Time Course of Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone.
fentanyl
nalmefene
naloxone
opioid antagonist
opioid overdose
pharmacodynamics
pharmacokinetics
respiratory depression reversal
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
08
03
2024
accepted:
26
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
The increase in opioid overdose deaths, particularly involving potent, long-acting synthetic opioids, has led to calls for stronger, longer-acting opioid-overdose-reversal agents. Using an opioid-induced respiratory depression model, we investigated the onset and time course of action of naloxone and a long-acting opioid antagonist, nalmefene, in reversing the effects of an ongoing intravenous fentanyl infusion over a period of up to 100 min. Healthy, moderately experienced opioid users received intramuscular (IM) nalmefene 1 mg, IM naloxone 2 mg, or intranasal (IN) naloxone 4 mg after fentanyl-induced respiratory depression was established based on reduction in respiratory minute volume (MV). Each participant received each opioid antagonist twice per a randomized crossover schedule. Reversal of respiratory depression, pharmacokinetics, and safety were investigated. Participants showed rapid increases in plasma opioid antagonist concentrations, and meaningful reversal of depressed MV tended to occur earlier with IM nalmefene and IM naloxone than with IN naloxone. Compared to naloxone, nalmefene provided extended exposure, and mean MV was maintained at a higher level. All participants experienced treatment-related adverse events, but none were severe, serious, or led to study drug discontinuation. This study provides evidence that IM nalmefene 1 mg achieves reversal of fentanyl-induced respiratory depression similar to or better than that achieved with standard-of-care naloxone treatments. No new safety concerns were raised for IM nalmefene at the tested dose. The pharmacokinetic and pharmacodynamic properties of IM nalmefene position it as an important treatment option in opioid overdose reversal, particularly given the increasing prevalence of overdoses involving potent, long-acting synthetic opioids.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Références
O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U‐47700—10 States, July‐December 2016. MMWR Morb Mortal Wkly Rep. 2017;66(43):1197‐1202.
O'Donnell J, Gladden RM, Mattson CL, Kariisa M. Notes from the field: overdose deaths with carfentanil and other fentanyl analogs detected—10 States, July 2016‐June 2017. MMWR Morb Mortal Wkly Rep. 2018;67(27):767‐768.
Baldwin GT, Seth P, Noonan RK. Continued increases in overdose deaths related to synthetic opioids: implications for clinical practice. JAMA. 2021;325(12):1151‐1152.
Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202‐207.
Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2021. Accessed March 28, 2022. https://www.cdc.gov/nchs/nvss/vsrr/drug‐overdose‐data.htm
Rising numbers of deaths involving fentanyl and fentanyl analogs, including carfentanil, and increased usage and mixing with non‐opioids. Health Alert Network, CDC. 2018. Accessed April 25, 2022. https://emergency.cdc.gov/han/han00413.asp
Armenian P, Vo KT, Barr‐Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology. 2018;134(Pt A1):121‐132.
Shafi A, Berry AJ, Sumnall H, Wood DM, Tracy DK. Synthetic opioids: a review and clinical update. Ther Adv Psychopharmacol. 2022;12:20451253221139616.
Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology. 1999;90(2):576‐599.
Ahonen J, Olkkola KT, Hynynen M, et al. Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. Br J Anaesth. 2000;85(4):533‐540.
Fentanyl citrate injection, for intravenous use, CII. Full prescribing information. Exela Pharma Sciences, LLC. Accessed 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215870s000lbl.pdf
Faul M, Lurie P, Kinsman JM, Dailey MW, Crabaugh C, Sasser SM. Multiple naloxone administrations among emergency medical service providers is increasing. Prehosp Emerg Care. 2017;21(4):411‐419.
Klebacher R, Harris MI, Ariyaprakai N, et al. Incidence of naloxone redosing in the age of the new opioid epidemic. Prehosp Emerg Care. 2017;21(6):682‐687.
Volkow ND. The epidemic of fentanyl misuse and overdoses: challenges and strategies. World Psychiatry. 2021;20(2):195‐196.
FDA approves naloxone injection to counteract opioid overdoses [press release]. U.S. Food & Drug Administration. 2021. Accessed 2022. https://www.fda.gov/drugs/news‐events‐human‐drugs/fda‐approves‐naloxone‐injection‐counteract‐opioid‐overdoses
FDA approves higher dosage of naloxone nasal spray to treat opioid overdose [press release]. U.S. Food & Drug Administration. 2021. https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐higher‐dosage‐naloxone‐nasal‐spray‐treat‐opioid‐overdose
Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacol Ther. 2021:108019.
Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391‐394.
Kim S, Wagner HN, Jr, Villemagne VL, et al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual‐detector system. J Nucl Med. 1997;38(11):1726‐1731.
Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid‐induced respiratory depression. Anesthesiology. 2010;112(1):226‐238.
Toll L, Berzetei‐Gurske IP, Polgar WE, et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr. 1998;178:440‐466.
Edinoff AN, Nix CA, Reed TD, et al. Pharmacologic and clinical considerations of nalmefene, a long duration opioid antagonist, in opioid overdose. Psychiatry Int 2021;2(4):365‐378.
Cassel JA, Daubert JD, DeHaven RN. [(3)H]Alvimopan binding to the mu opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005;520(1‐3):29‐36.
Drugs@FDA: FDA‐approved drugs. REVEX (nalmefene hydrochloride injection). U.S. Food & Drug Administration. Accessed April 17, 2023. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020459
Determination that REVEX (nalmefene hydrochloride injection), 0.1 milligram base/milliliter and 1.0 milligram base/milliliter, was not withdrawn from sale for reasons of safety or effectiveness. Federal Register. 2017. Accessed March 18, 2022. https://www.federalregister.gov/documents/2017/11/03/2017‐23952/determination‐that‐revex‐nalmefene‐hydrochloride‐injection‐01‐milligram‐basemilliliter‐and‐10
FDA approves Nalmefene HCl injection, 2mg/2mL (1mg/1mL) for the treatment of known or suspected opioid overdose with natural or synthetic opioids [press release]. Purdue Pharma L.P. 2022. Accessed March 14, 2022. https://www.purduepharma.com/news/2022/02/23/fda‐approves‐nalmefene‐hcl‐injection‐2mg‐2ml‐1mg‐1ml‐for‐the‐treatment‐of‐known‐or‐suspected‐opioid‐overdose‐with‐natural‐or‐synthetic‐opioids/
Nalmefene hydrochloride injection, solution. Full prescribing information. Purdue Pharma LP. 2022. Accessed May 13, 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3abfbffc‐9e52‐4fc6‐ae92‐6e0a97f4afe7
Kaplan JL, Marx JA. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study. Ann Emerg Med. 1993;22(2):187‐190.
Kaplan JL, Marx JA, Calabro JJ, et al. Double‐blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann Emerg Med. 1999;34(1):42‐50.
Stoeckel H, Schuttler J, Magnussen H, Hengstmann JH. Plasma fentanyl concentrations and the occurrence of respiratory depression in volunteers. Br J Anaesth. 1982;54(10):1087‐1095.
Glass PS, Jhaveri RM, Smith LR. Comparison of potency and duration of action of nalmefene and naloxone. Anesth Analg. 1994;78(3):536‐541.
Mildh LH, Scheinin H, Kirvela OA. The concentration‐effect relationship of the respiratory depressant effects of alfentanil and fentanyl. Anesth Analg. 2001;93(4):939‐946.
Algera MH, Olofsen E, Moss L, et al. Tolerance to opioid‐induced respiratory depression in chronic high‐dose opioid users: a model‐based comparison with opioid‐naive individuals. Clin Pharmacol Ther. 2021;109(3):637‐645.
Ellison M, Hutton E, Webster L, Skolnick P. Reversal of opioid‐induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone. J Clin Pharmacol. 2024;64(7):828‐839.
Voscopoulos C, Brayanov J, Ladd D, Lalli M, Panasyuk A, Freeman J. Special article: evaluation of a novel noninvasive respiration monitor providing continuous measurement of minute ventilation in ambulatory subjects in a variety of clinical scenarios. Anesth Analg. 2013;117(1):91‐100.
Voscopoulos CJ, MacNabb CM, Freeman J, Galvagno SM, Jr., Ladd D, George E. Continuous noninvasive respiratory volume monitoring for the identification of patients at risk for opioid‐induced respiratory depression and obstructive breathing patterns. J Trauma Acute Care Surg. 2014;77(3 Suppl 2):S208‐215.
Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. Marcel Dekker, Inc.; 1982.
Amur S, Xu Y, Hertz S, Clingman C. FDA experience with regulation of naloxone products to address the opioid crisis and opportunities for leveraging scientific engagement. Clin Pharmacol Ther. 2021;109(3):569‐572.
Konieczko KM, Jones JG, Barrowcliffe MP, Jordan C, Altman DG. Antagonism of morphine‐induced respiratory depression with nalmefene. Br J Anaesth. 1988;61(3):318‐323.
Nallani S, Smith LT, Uppoor RS, Mehta MU. Reversal of high potency synthetic opioid overdose: literature review [poster]. Paper presented at: The 2021 FDA Science Forum. 2021. https://www.fda.gov/science‐research/fda‐science‐forum/reversal‐high‐potency‐synthetic‐opioid‐overdose‐literature‐review